June brought new leadership appointments at the AfPH, a new AfPH webinar, fresh research on sotatercept, and continued momentum in the PAH pipeline. Here’s our roundup of the month’s key developments:
🏆 AfPH announcements
- Introducing AfPH’s New Board of Directors 2026–2029: President Pisana Ferrari (Italy), Vice President Louise Bouman (Netherlands), Treasurer Ioanna Alyssandratou (Greece), Secretary Laure RosĂ© (France). The new Board includes dedicated patient advocates bringing decades of combined experience in the PH field.
🏆Community and recognition
- Congratulations to Louise Bouman, AfPH Vice President, on her election as Chair of the United Patient Advisory Group of the European Lung Foundation (ELF)!
- Ayotunde Omitogun, founder of the Cardiac Community in Nigeria, receives the 2026 Rino Aldrighetti Leadership Award (PHA), June 18
🔬 Research & Clinical Studies
- How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept — Chest Journal, June 24
- Could sotatercept be effective in end-stage bronchiolitis obliterans syndrome after lung transplant? — Journal of Heart and Lung Transplant, August 2026 edition •
- Haemodynamic responses to sotatercept and parenteral prostacyclins in PAH — Journal of Heart and Lung Transplantation, June 1
- Roundtable of US pulmonologists on sotatercept, de-escalation, and the limits of upfront therapy — HCP Live, June 22
- Exploring GLP-1 receptor agonists in PAH — European Respiratory Journal, May 2026
- Upfront triple combination therapy with selexipag: a real-world cohort in Chinese PAH patients — Frontiers in Cardiovascular Medicine, May 21
- Web-based survey explores patient perspectives on palliative care in PAH in the US — Pulmonary Circulation, June 24
- Japanese Circulation Society publishes lay summary of PH guidelines, responding to PHA Japan advocacy, June 8
đź’Š Industry & Drug Development
- Liquidia (LQDA) presents new YUTREPIA data at PHA’s International Conference, Dallas, June 11–14
- Corsair Pharma presents Phase 1 data for TRX-248 Transdermal System at the 2026 PHA Conference
- Regeneron expands into PAH with Phase 2 trial for REGN13335
🏛️ Governance & Policy
- Do financial conflicts of interest influence prescribing practices? Yale study — Medical XPress, June 16
🎥 Webinars & Events
- June 23 AfPH webinar – “When Science and AI Converge: the Evolving Landscape of PAH Care” — slides & transcript available online on the PH Knowledge Sharing Platform
- Coming up! Inhaled Therapies for Pulmonary Hypertension: Where We Are and What’s Next — Live PHA webinar, July 23, 2pm EDT